Published in J Immunol on August 15, 2005
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Principles of adoptive T cell cancer therapy. J Clin Invest (2007) 2.65
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med (2013) 1.78
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A (2012) 1.58
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51
The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol (2008) 1.51
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood (2007) 1.50
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood (2010) 1.29
IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J Immunol (2010) 1.28
IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS One (2008) 1.28
Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med (2016) 1.24
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med (2009) 1.19
Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect (2010) 1.17
Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes (2011) 1.11
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep (2012) 1.07
Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells. Haematologica (2011) 1.04
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev (2014) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J Allergy Clin Immunol (2013) 1.01
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med (2013) 1.00
IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol (2009) 1.00
Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep (2012) 0.97
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc (2014) 0.95
Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother (2010) 0.95
Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res (2008) 0.94
Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res (2008) 0.94
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol (2016) 0.93
Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica (2011) 0.91
Interleukin-21 stimulates antigen uptake, protease activity, survival and induction of CD4+ T cell proliferation by murine macrophages. Clin Exp Immunol (2008) 0.91
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother (2009) 0.89
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res (2012) 0.89
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer (2014) 0.89
Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One (2014) 0.88
Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res (2011) 0.88
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood (2016) 0.86
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol (2010) 0.85
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol (2016) 0.84
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res (2014) 0.84
IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 0.83
Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development. Immunology (2013) 0.83
IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J Immunol (2012) 0.83
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
The smallest unit: effector and memory CD8(+) T cell differentiation on the single cell level. Front Immunol (2013) 0.82
Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res (2013) 0.82
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol (2015) 0.82
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol (2010) 0.81
Post-transplant adoptive T-cell immunotherapy. Best Pract Res Clin Haematol (2008) 0.81
Interleukin 21 up-regulates perforin-mediated cytotoxic activity of human intra-epithelial lymphocytes. Immunology (2009) 0.81
The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort. Clin Exp Immunol (2013) 0.81
IL-21R expression on CD8+ T cells promotes CD8+ T cell activation in coxsackievirus B3 induced myocarditis. Exp Mol Pathol (2012) 0.81
Association between IL-21 gene rs907715 polymorphisms and Graves' disease in a Southern Chinese population. Exp Ther Med (2014) 0.79
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunol Immunother (2013) 0.79
A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J Transl Med (2016) 0.79
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8(+) T Cells In Vivo. Sci Immunol (2017) 0.78
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Antigen-specific human NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of immunoglobulins. Oncotarget (2015) 0.78
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol (2016) 0.78
Th17 cell enhances CD8 T-cell cytotoxicity via IL-21 production in emphysema mice. Mediators Inflamm (2012) 0.77
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma. Sci Rep (2014) 0.77
Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. J Transl Med (2015) 0.77
Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma. Int J Mol Sci (2015) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology (2016) 0.75
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Th-17 regulatory cytokines inhibit corticosteroid induced airway structural cells apoptosis. Respir Res (2016) 0.75
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Autoreactive T cells in healthy individuals. J Immunol (2004) 2.29
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell (2003) 2.28
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med (2013) 1.78
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Dissolution chemistry and biocompatibility of single-crystalline silicon nanomembranes and associated materials for transient electronics. ACS Nano (2014) 1.66
Ultra-sensitive detection of rare T cell clones. J Immunol Methods (2011) 1.64
CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol (2008) 1.60
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A (2012) 1.58
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One (2009) 1.51
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood (2007) 1.50
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest (2002) 1.39
Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res (2011) 1.36
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A (2005) 1.36
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res (2011) 1.27
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest (2015) 1.13
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer (2012) 1.13
Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant (2006) 1.04
Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol (2006) 1.00
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One (2012) 0.94
A multimodal targeting nanoparticle for selectively labeling T cells. Small (2008) 0.93
Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res (2013) 0.93
Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med (2007) 0.93
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol (2013) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother (2012) 0.88
NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol (2010) 0.85
Immune-based therapies for sarcoma. Sarcoma (2011) 0.84
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol (2010) 0.81
Immunologic and tissue biocompatibility of flexible/stretchable electronics and optoelectronics. Adv Healthc Mater (2013) 0.79
NKG2D ligation relieves 2B4-mediated NK-cell self-tolerance in mice. Eur J Immunol (2014) 0.76
Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett (2012) 0.76
Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. Blood (2002) 0.75
Another LAP in the race. Cancer Discov (2012) 0.75